Introduction
============

Despite striking improvement in diagnosis and treatment, lung cancer remains the leading cause of cancer-related death worldwide. Non-small cell lung cancer is predominantly comprised of adenocarcinomas and squamous cell carcinomas, accounting for approximately 85% of all lung cancer cases. Recent advancements in immunotherapy with anti‑programmed death‑1 (PD‑1) monoclonal antibodies have led to a major paradigm shift in the treatment of NSCLC.

PD-1 is a member of the cluster of differentiation (CD) 28 family expressed on T cells, natural killer cells, monocytes and B cells. As an immune checkpoint receptor, it plays a crucial role in immune escape during tumor progression [@B1]-[@B4]. PD-1 ligands programmed death ligand 1 (PD-L1, CD274) and programmed death ligand 2 (PD-L2, CD273) are known to be negative immune regulators which interact with PD-1 to block cytotoxic T cell activity and facilitate tumor immune evasion [@B1], [@B5]. Immunotherapy with anti-PD-L1 or anti-PD-1 antibodies has successfully shown significant antitumor activities in various cancers including NSCLC [@B6]-[@B8]. As such, the durable clinical responses to nivolumab, pembrolizumab and atezolizumab have led to their rapid approval as second-line therapy for NSCLC [@B9]. However, overall response rates to these agents are still low, thus evaluation of the expression patterns of PD-L1/PD-L2 might provide valuable information to predict benefit to immunotherapies.

To date, the clinicopathological features related to PD-L1 and PD-L2 expression for patients with NSCLC remain controversial. Several studies have investigated the relation between PD-L1 expression and smoking history. Several groups detected higher PD-L1 expression in resected NSCLC patients who had a smoking history compared non/low-smokers [@B10]-[@B12], while another investigation found no relationship [@B13]. Furthermore, some studies have observed that squamous cell carcinoma patients exhibited significantly higher expression of PD-L1 [@B10], [@B11], [@B14] while others found it correlated with adenocarcinoma [@B12]. While serum tumor markers including carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), cytokeratin-19 fragments (Cyfra21-1) and squamous cell carcinoma antigen (SCCA), are considered to be associated with lung cancer histology and to be predictive or prognostic in NSCLC, they have not been well investigated in relation to PD-L1/PD-L2 expression. In addition, there is not a consensus regarding the prognostic significance of PD-L1/PD-L2 expression in NSCLC.

In the present study, we investigated PD-L1 and PD-L2 expression in resected lung adenocarcinoma and squamous cell carcinoma and evaluated their association with clinicopathologic and molecular parameters, including epidermal growth factor receptor (EGFR) status, smoking history, age, sex, regional lymph node metastasis, clinical stage, tumor size as well as serum tumor markers. In addition, the prognostic value of PD-L1 and PD-L2 expression was examined.

Materials and methods
=====================

Patients and specimens
----------------------

The retrospective cohort consisted of 364 patients (158 squamous cell carcinoma and 206 adenocarcinoma) who underwent surgical resection between 2009 and 2012 at the Tianjin Cancer Institute & Hospital, Tianjin Medical University, Tianjin P.R. China. Pathologic diagnosis and clinicopathologic staging of the specimens were performed according to World Health Organization (WHO) histological classification and tumor-node-metastasis (TNM) classification system (AJCC, 1977). Patients who accepted any anti-tumor therapy (radiotherapy, chemotherapy or targeted therapy) before surgery, who died within two months after surgery or died of any other reason, were excluded for analysis. Tissue microarrays (TMA; 2mm in diameter) were constructed using the most representative areas of the formalin-fixed paraffin embedded (FFPE) NSCLC tissues. In total, 158 patients with squamous cell carcinoma and 206 patients with adenocarcinoma were included and basic clinical parameters were recorded. Prior consent from all patients and approval from the Research Ethics Committee of Tianjin University were obtained for the use of clinical and pathological data.

Measurement of serum CEA, NSE, SCCA and Cyfra21-1 levels and EGFR mutations
---------------------------------------------------------------------------

All of the serum tumor marker levels were measured within two weeks before surgery using electrochemiluminescence immunoassay on a Roche Analytics E170 Immunology Analyzer (Roche Diagnostics, China). The cut-offs for serum marker levels were stipulated as follows according to manufacturer\'s recommendation: CEA 5.0 ng/ml, NSE 15.2 ng/ml, SCCA 1.5 ng/ml, and Cyfra21-1 3.3 ng/ml. EGFR mutations, including EGFR exon 19 deletion (del19) and exon 21 Leu858Arg substitution (L858R), were identified by real-time PCR or DNA sequencing as previously described [@B15], [@B16]. Other EGFR mutations were not tested for.

Immunohistochemistry
--------------------

TMA blocks were sectioned at a thickness of 4μm, and immunohistochemistry (IHC) was performed using the following antibodies: rabbit anti-PD-L1 XP^®^ mAb (1:100, EIL3N, Cell Signaling Technology, Danvers, MA, USA), mouse anti-PD-L2 mAb (1:200, clone 176611, R&D system, Minneapolis, MN, USA). Briefly, sections were deparaffinized with xylene followed by an ethanol gradient. EDTA buffer was used for antigen unmasking, and sections were then incubated in 3% hydrogen peroxide. After washing with Tris Buffered Saline with Tween^®^ 20 (TBST), slides were incubated overnight at 4°C with primary antibodies. The expression of PD-L1 and PD-L2 were detected using ChemMate EnVision Detection Kit with DAB substrate (Dako, Carpinteria, CA, USA) following the manufacturer\'s instruction with modification as described previously [@B17], [@B18].

The slides were blindly examined by two investigators. The slides were reviewed together to achieve consensus if the independent assessments did not agree. Tumor cells showing membranous staining for PD-L1 were considered as positive cells. We set the cut-off values at 1%, 5%, 10% and 50% for PD-L1 expression. PD-L2 IHC was scored as: 0 (no staining), 1+ (cytoplasmic and/or weak membranous staining in \< 50% of the tumor cells), 2+ (weak to moderate membranous staining in ≥ 50% of the tumor cells), and 3+ (strong membranous staining in ≥ 50% of the tumor cells). Specimens that scored as 2+ or 3+ were considered to be positive for PD-L2 expression (Figure [1](#F1){ref-type="fig"}).

Statistical analysis
--------------------

SPSS 20.0 software (IBM Corporation, Armonch, NY, USA) was used for all statistical analyses. Univariate analyses of the relation between PD-L1 and PD-L2 and clinicopathologic parameters were performed using Chi-squared test or Fisher exact test, while multivariate analyses were performed by logistic regression analysis with the backward elimination method. Disease-free survival (DFS) was defined as the period from surgery to date of the recurrence, and overall survival (OS) was defined as the period from surgery to the date of the last follow-up or death. Cox proportional hazards regression analyses were performed to assess the hazard ratios for positive risk factors with the backward elimination method. Differences were considered statistically significant at a two-sided p-value of \< 0.05.

Results
=======

Patient characteristics
-----------------------

The clinicopathologic characteristics of the patients were summarized in Table [1](#T1){ref-type="table"}. Among 364 patients, there were 228 (62.6%) males and 136 (37.4%) females with a median age of 59.5 years (range, 32-82 years), and 161 (44.2%) patients were smokers with smoking index greater than or equal to 400. At the time of diagnosis, 175 (48.1%) patients were at stage I, 72 (19.8%) were at stage II and 177 (32.1%) were at stage IIIA. Thirty-seven patients (10.2%) received pneumonectomy, 313 (86.0%) received lobectomy, and 14 (3.8%) underwent wedge resection. Of all surgically resected patients, 221 (60.7%) patients received adjuvant treatment. The EGFR mutation rate was 17.6% (64/364) among all NSCLC patients, 29.1% (60/206) within adenocarcinoma (Table [S1](#SM0){ref-type="supplementary-material"}) and 2.5% (4/158) within squamous cell carcinoma cohorts (Table [S2](#SM0){ref-type="supplementary-material"}), respectively.

Association of PD-L1 and PD-L2 expression with clinicopathological features
---------------------------------------------------------------------------

PD-L1 expression was present in 202 (55.5%), 151 (41.5%), 122 (33.5%) and 81 (22.3%) cases when using cutoff values of 1%, 5%, 10% and 50%, respectively. PD-L2 was positively expressed in 179 (49.2%) patients. In univariate analysis (Table [2](#T2){ref-type="table"}), PD-L1 expression was significantly associated with moderate/heavy smoking history (SI ≥400) for all cutoffs (P \< 0.001 for 1%, 5% and 10% cutoffs, p = 0.005 for 50% cutoff). PD-L1 expression was more prevalent in male gender for 1% (P = 0.039) and 50% (P = 0.170) cutoffs. Positive lymph node metastasis was associated with PD-L1 expression for 50% cutoff (P = 0.017), but not for 1%, 5% or 10% cutoffs. Squamous cell carcinoma had a nonsignificant trend towards higher PD-L1 expression compared with adenocarcinoma (P = 0.072 for 10% cutoff, P = 0.138 for 50% cutoff). Interestingly, PD-L1 expression was closely correlated with serum SCCA level for almost all cutoffs (P = 0.200 for 1% cutoff, P = 0.004 for 5% cutoff, P = 0.009 for 10% cutoff and P = 0.001 for 50% cutoff). There was no correlation between PD-L1 expression and clinical stage or EGFR status. We also analyzed the relation between PD-L2 expression and the clinicopathological factors, but no statistically significant correlation was found (Table [S3](#SM0){ref-type="supplementary-material"}). Multivariate analysis revealed that moderate/heavy smoking history was associated with PD-L1 expression for all cutoffs, while SCCA level was associated with PD-L1 expression for all cutoffs except at 1% (Table [S4](#SM0){ref-type="supplementary-material"}).

Additional sub-analyses of different histological subtypes showed that PD-L1 expression correlated with moderate/heavy smoking history (SI ≥ 400), larger tumor size, solid type adenocarcinoma, serum Cyfra21-1, and serum SCCA in adenocarcinoma for different cutoffs (Table [S1](#SM0){ref-type="supplementary-material"}). Conversely, a significant association was found between PD-L1 expression and female gender, moderate/heavy smoking history (SI ≥ 400), positive regional lymph node metastasis and wild type EGFR in squamous cell carcinoma for different cutoffs (Table [S2](#SM0){ref-type="supplementary-material"}).

Prognostic significance of PD-L1 and PD-L2 in NSCLC
---------------------------------------------------

Median overall survival and disease-free survival of the total 364 patients were 38.0 months and 23.7 months, respectively. We assessed the association between PD-L1 expression and patient postoperative survival at four PD-L1 cutoff values. Univariate analysis showed that patients with high PD-L1 positivity shared significantly shorter DFS (hazard ratio \[HR\] 1.546, P = 0.004) and OS (HR 1.704, P = 0.002) than those with low PD-L1 expression at a 50% cutoff value (Table [3](#T3){ref-type="table"}) (Figure [2](#F2){ref-type="fig"}), but not at 1%, 5% or 10% (Figure [S1](#SM0){ref-type="supplementary-material"}). Survival analysis was also used to assess the associations between PD-L2 expression and patient postoperative survival. Though no significantly association was found between PD-L2 expression and survival (either DFS or OS), patients with negative PD-L2 expression tended to have relatively longer DFS (HR 1.276, P = 0.063) (Table [3](#T3){ref-type="table"}) (Figure [S1](#SM0){ref-type="supplementary-material"}). On the basis of these results, we adopted 50% cutoff value for further survival analyses. Univariate analysis showed besides 50% cutoff for PD-L1 expression, smoking history, clinical stage, regional lymph node metastasis, serum CEA, and serum SCCA were associated with significantly shorter DFS and OS. Additionally, patients who underwent adjuvant treatment and had elevated serum Cyfra21-1 levels shared a longer OS. To identify prognostic factors, we used multivariate analysis using the Cox regression model adjusted for all factors. PD-L1 positivity remained a predictor of DFS and OS at the 50% cutoff value. Moreover, smoking history, advanced clinical stage, larger tumor size, elevated serum CEA and elevated serum SCCA remained independent risk factors for DFS, while smoking history, advanced clinical stage, no adjuvant therapy, elevated serum CEA level and elevated serum Cyfra21-1 level were poor prognostic indicators for OS (Table [3](#T3){ref-type="table"}).

Prognostic significance of PD-L1 expression for 50% cutoff in subgroups
-----------------------------------------------------------------------

To investigate PD-L1\'s clinical significance, patients were further divided into subgroups according to histology (adenocarcinoma vs. squamous cell carcinoma), serum SCCA level (≤ 1.5 ng/ml vs. \> 1.5 ng/ml) and smoking history (SI \< 400 vs. SI ≥ 400).

Univariate analysis showed that PD-L1 expression at a 50% cutoff was associated with significantly short DFS and OS only in patients with squamous cell carcinoma (DFS: HR 2.149, P = 0.001; OS: HR 2.380, P \< 0.001) but not adenocarcinoma. In patients with elevated SCCA, a significant association was found between PD-L1 expression and survival (DFS: HR 2.479, P = 0.001; OS: HR 2.145, P = 0.011), while no association was found between PD-L1 expression and survival in patients with low serum SCCA. Moreover, high PD-L1 expression was also associated with poor survival in patients with moderate/heavy smoking history (SI ≥ 400, DFS: HR 1.704, P = 0.010; OS: HR 2.028, P = 0.002) (Table [4](#T4){ref-type="table"}) (Figure [2](#F2){ref-type="fig"}).

Discussion
==========

The association between PD-L1/PD-L2 expression and clinicopathological characteristics, as well as the prognostic significance of PD-L1/ PD-L2 in NSCLC remain unclear. We performed this study to identify factors closely related to PD-L1 and PD-L2 expression, and to elucidate the role of PD ligands as predictive and prognostic markers of survival in NSCLC patients.

We demonstrated a close relationship between PD-L1 expression, serum SCCA, and moderate/heavy smoking history. PD-L1 expression was also related to regional lymph node metastasis. High expression of PD-L1 was an independent unfavorable predictor of survival. Moreover, PD-L1 association with adverse prognosis differed by serum SCCA, moderate/strong smoking history and histological subtype. To our knowledge, this is the first study uncovers an intriguing correlation between PD-L1 expression and serum SCCA.

Recent studies have investigated PD-L1 protein expression in association with EGFR mutation [@B19]-[@B26]. However, some reports found that PD-L1 expression was higher in patients with EGFR mutations compared to those with wild-type EGFR [@B19], [@B25], while in other studies the reverse was true [@B11], [@B27]. We found no significant correlation between PD-L1 expression and EGFR mutation status in NSCLC, which was consistent with other groups [@B20], [@B21]. These discrepancies may due to the differences in histological cell types and/or disease stages analyzed, different antibodies used, and/or different criteria employed for PD-L1 expression. Therefore, more studies are required to verify the association between PD-L1 expression and mutant EGFR status in NSCLC patients.

We found a significant association between regional lymph node metastasis and PD-L1 protein expression when using a 50% cutoff. This association was observed in both adenocarcinoma and squamous cell carcinomas when patients were stratified according to histology. Several previous studies identified a similar relationship between lymph node metastasis and PD-L1 expression (Table [S5](#SM0){ref-type="supplementary-material"}).

Additionally, our results showed that PD-L1 expression was higher in solid predominant tumors compared to other adenocarcinoma subtypes consistent with other reports [@B11], [@B27], [@B28]. The solid predominant subtype is associated with poorer prognoses compared with other subtypes [@B29].

Many recent studies have evaluated the prognostic value of PD-L1 expression in NSCLC [@B10]-[@B14], [@B20], [@B21], [@B27], [@B28], [@B30]-[@B32]. While we and others observed high PD-L1 expression associated with poorer prognosis [@B10], [@B12], [@B27], [@B32], some studies found either a favorable prognosis [@B20], [@B21], [@B30] or lack of association [@B13], [@B28]. This discrepancy may be due to the different anti-PD-L1 antibodies used, different clinical stage of the whole cohorts, different distribution of histological subtype and different criteria of defining the positivity of PD-L1 expression. PD-L1 appeared to be a favorable prognostic factor only for stage I patients in one study [@B21], while another cohort included some advanced stage patients and used AQUA score to assess the PD-L1 expression, which was not commonly used [@B30]. Two other groups found no correlation between PD-L1 expression or prognosis unlike our results, even when using the same E1L3N PD-L1 antibody and cutoffs [@B13], [@B28]. However, our findings of high PD-L1 expression associated with poor prognosis were consistent with two studies which used E1L3N for IHC [@B14], [@B32]. PD-L1 positivity thresholds of 1% or 50% positive PD-L1 expression have been shown to be significantly prognostic [@B10], [@B32]. While we tested 1%, 5%, 10% and 50% PD-L1 thresholds, only the 50% cutoff was prognostically significant. Our study showed that PD-L1 expression was significantly higher in patients with moderate/heavy smoking history and elevated serum SCCA levels and served as a prognostic marker in these subsets of patients. Because PD-L1 expression improves likelihood of NSCLC patient response to anti-PD-1/PD-L1 treatment [@B33], it is reasonable to hypothesize that moderate/heavy smoking history and high serum SCCA level may also have predictive value to this PD-1/PD-L1 blockade. In support of this, a correlation has been observed between smoking signature and the efficacy of anti-PD-1/PD-L1 inhibitors [@B34]. NSCLC patients with smoking history and smoking-associated lung squamous cell carcinoma had larger somatic mutation burdens [@B35], [@B36]. Studies based on the Cancer Genome Atlas project revealed recently that NSCLC had the greatest mutational burden per cell compared with other solid tumors, and had the significant sensitivity to anti-PD-1/PD-L1 antibody therapy as well [@B36], [@B37]. Somatic mutations could increase recognition of neoantigens, one important factor for successful immunotherapy. Though two recent large phase III studies that compared the efficacy of an anti-PD-1 antibody did not observe significantly different efficacies between squamous cell carcinoma and non-squamous cell carcinoma [@B6], [@B7], these histology types can exhibit different PD-L1 levels [@B10], [@B11], [@B38]. Clinical studies suggested that patients with higher PD-L1 expression could benefit more from anti-PD-1/PD-L1 inhibitors after a first-line therapy [@B6], [@B33]. In our study, PD-L1 was significantly prognostic in patients with elevated serum SCCA. Although SCCA is believed to produce only by squamous epithelial cells, it is unclear whether alterations in serum SCCA levels actually represent an intratumor squamous-rich component in NSCLC. Taken together, this suggests that the prognostic value of PD-L1 exists not only in patients with squamous cell carcinoma, but also in adenocarcinoma patients with elevated serum SCCA.

As to PD-L2 expression, we evaluated the association between PD-L2 expression and clinicopathologic and molecular parameters, including EGFR status, smoking history, age, sex, regional lymph node metastasis, clinical stage, tumor size as well as serum tumor markers, but no relationship was observed. Meanwhile, we found PD-L2 could not predict OS or PFS for NSCLC patients in our study, which is consistent with the studies of Jun et al. [@B39] and Kim et al. [@B24].

Our study has several limitations. This was a single institutional retrospective study and not a trial-based correlative study. We did not use the companion diagnostic antibodies used for the 3 corresponding FDA approved anti-PD-1/PD-L1 antibodies (pembrolizumab, atezolizumab and nivolumab). Dako/Agilent 28-8 assay was used for nivolumab, Dako/Agilent 22C3 assay for pembrolizumab, and the Ventana SP142 assay for atezolizumab. However, a recent study compared the concordance of 4 PD-L1 antibodies including 28-8, 22C3, SP142 and E1L3N, found that the assay using the SP142 antibody is an outlier while E1L3N, used in our study, together with 28-8 and 22C3 appeared to be interchangeable from an analytic perspective [@B40]. Additionally, our immunohistochemistry was performed on TMAs. TMAs may underrepresent tumor heterogeneity than the whole tissue sections, and TMAs are not used as standard diagnostic samples. Therefore, further studies of the association between PD-L1 expression and the clinicopathological characteristics as well as prognoses are warranted.

Conclusion
==========

In conclusion, we observed that PD-L1 expression was correlated with moderate/heavy smoking history and elevated serum SCCA in NSCLC, and was an independently poor predictor of survival. We have shown that the prognostic value of PD-L1 expression differed by SCCA level, moderate/heavy smoking history and histology subtype.
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![Kaplan-Meier survival curves of DFS (A) and OS (B) according to PD-L1 expression at a 50% cutoff value (negative vs. positive) in NSCLC patients. Kaplan-Meier survival curves of DFS (C, E, G) and OS (D, F, H) based on PD-L1 expression status (negative vs. positive) in patients with moderate/heavy-smoking (SI ≥ 400) (C, D), elevated serum SCCA level (SCCA \> 1.5 ng/ml) (E, F) and squamous cell carcinoma(G, H). SI: smoking index = (number of cigarettes per day) × (duration in years).](jcav08p3251g002){#F2}

###### 

Clinicopathological Characteristics of All Patients.

  Variables                    Number of patients   \%
  ---------------------------- -------------------- ------
  **Age (years)**                                   
  Median (range)               59 (32-82)           
  ≤ 60                         188                  51.6
  \> 60                        176                  48.4
  **Gender**                                        
  Male                         228                  62.6
  Female                       136                  37.4
  **Smoking Index (SI)**                            
  SI \< 400                    203                  55.8
  SI ≥ 400                     161                  44.2
  **Clinical stage**                                
  I                            175                  48.1
  II                           72                   19.8
  IIIA                         177                  32.1
  **Tumor size**                                    
  ≤ 3 cm                       167                  45.9
  \> 3 cm                      197                  54.1
  **Regional LN metastasis**                        
  No                           204                  56.0
  Yes                          160                  44.0
  **Histology**                                     
  AD                           206                  56.6
  SCC                          158                  43.4
  **Operative approaches**                          
  Pneumonectomy                37                   10.2
  Lobectomy                    313                  86.0
  Wedge resection              14                   3.8
  **Adjuvant treatment**                            
  No                           221                  60.7
  Yes                          143                  39.3
  **EGFR mutation**                                 
  No                           300                  82.4
  Yes                          64                   17.6
  **NSE**                                           
  ≤ 15.2 ng/ml                 249                  68.4
  \> 15.2 ng/ml                115                  31.6
  **CEA**                                           
  ≤ 5.0 ng/ml                  238                  65.4
  \> 5.0 ng/ml                 126                  34.6
  **Cyfra21-1**                                     
  ≤ 3.3 ng/ml                  195                  53.6
  \> 3.3 ng/ml                 169                  46.4
  **SCCA**                                          
  ≤ 1.5 ng/ml                  283                  77.7
  \> 1.5 ng/ml                 81                   22.3

LN: lymph node. AD: adenocarcinoma. SCC: squamous cell carcinoma. SI: smoking index = (number of cigarettes per day) × (duration in years).

###### 

The association between PD-L1 expression and the clinicopathological factors.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  \                            1% Cutoff    5% Cutoff    10% Cutoff   50% Cutoff                                                                                                                
  \                                                                                                                                                                                             
  Variables N (%)                                                                                                                                                                               
  ---------------------------- ------------ ------------ ------------ -------------- ------------ ------------ -------------- ------------ ------------ -------------- ------------ ----------- -----------
  **Age (years)**                                                                                                                                                                               

  \< 60                        188 (51.6)   87 (46.3)    101 (54.7)   0.482          114 (60.6)   74 (39.4)    0.396          126 (67.0)   62 (33.0)    0.822          147 (78.2)   41 (21.8)   0.833

  ≥ 60                         176 (48.4)   75 (42.6)    101 (57.4)                  99 (56.3)    77 (43.8)                   116 (65.9)   60 (34.1)                   136 (77.3)   40 (22.7)   

  **Gender**                                                                                                                                                                                    

  Male                         228 (62.6)   92 (40.4)    136 (59.6)   **0.039**      91 (66.9)    45 (33.1)    **0.012**      99 (72.8)    37 (27.2)    **0.049**      172 (75.4)   56 (24.6)   0.170

  Female                       136 (37.4)   70 (51.5)    66 (48.5)                   122 (53.5)   106 (46.5)                  143 (62.7)   85 (37.3)                   111 (81.6)   25 (18.4)   

  **Smoking Index (SI)**                                                                                                                                                                        

  SI \< 400                    203 (55.8)   121 (59.6)   82 (40.4)    **\< 0.001**   148 (72.9)   55 (27.1)    **\< 0.001**   159 (78.3)   44 (21.7)    **\< 0.001**   169 (83.3)   34 (16.7)   **0.005**

  SI ≥ 400                     161 (44.2)   41 (25.5)    120 (74.5)                  65 (40.4)    96 (59.6)                   83 (51.6)    78 (48.4)                   114 (70.8)   47 (29.2)   

  **Clinical stage**                                                                                                                                                                            

  I                            175 (48.1)   83 (47.4)    92 (52.6)    0.529          108 (61.7)   67 (38.3)    0.469          123 (70.3)   52 (29.7)    0.328          143 (81.7)   32 (18.3)   0.180

  II                           72 (19.8)    29 (40.3)    43 (59.7)                   41 (56.9)    31 (43.1)                   46 (63.9)    26 (36.1)                   55 (76.4)    17 (23.6)   

  IIIA                         117 (32.1)   50 (42.7)    67 (57.3)                   64 (54.7)    53 (45.3)                   73 (62.4)    44 (37.6)                   85 (72.6)    32 (27.4)   

  **Tumor size**                                                                                                                                                                                

  ≤ 3 cm                       167 (45.9)   75 (43.4)    98 (56.6)    0.674          109 (63.0)   64 (37.0)    0.098          121 (69.9)   52 (30.1)    0.183          135 (80.8)   32 (19.2)   0.192

  \> 3 cm                      197 (54.1)   87 (45.5)    104 (54.5)                  104 (54.5)   87 (45.5)                   121 (63.4)   70 (36.6)                   148 (75.1)   49 (24.7)   

  **Regional LN metastasis**                                                                                                                                                                    

  No                           204 (56.0)   94 (46.1)    110 (53.9)   0.495          125 (61.3)   79 (38.7)    0.228          142 (69.6)   62 (30.4)    0.154          168 (82.4)   36 (17.6)   **0.017**

  Yes                          160 (44.0)   68 (42.5)    92 (57.5)                   88 (55.0)    72 (45.0)                   100 (62.5)   60 (37.5)                   115 (71.9)   45 (28.1)   

  **Histology**                                                                                                                                                                                 

  AD                           206 (56.6)   94 (45.6)    112 (54.4)   0.622          127 (61.7)   79 (38.3)    0.166          145 (70.4)   61 (29.6)    0.072          166 (60)     40 (19.4)   0.138

  SCC                          158 (43.4)   68 (43.0)    90 (57.0)                   86 (54.4)    72 (45.6)                   97 (61.4)    61 (38.6)                   117 (74.1)   41 (25.9)   

  **EGFR mutation**                                                                                                                                                                             

  No                           300 (82.4)   132 (44.0)   168 (56.0)   0.674          174 (58.0)   126 (42.0)   0.665          200(66.7)    100 (33.3)   0.873          232 (77.3)   68 (22.7)   0.681

  Yes                          64 (17.6)    30 (46.9)    34 (53.1)                   39 (60.9)    25 (39.1)                   42 (65.6)    22 (34.4)                   51 (79.7)    13 (20.3)   

  **NSE**                                                                                                                                                                                       

  ≤15.2 ng/ml                  249 (68.4)   112 (45.0)   137 (55.0)   0.789          174 (59.0)   102 (41.0)   0.767          167 (67.1)   82 (32.9)    0.728          196 (78.7)   53 (21.3)   0.514

  \>15.2 ng/ml                 115 (31.6)   50 (43.5)    65 (56.5)                   66 (57.4)    49 (42.6)                   75 (65.2)    40 (34.8)                   87 (75.7)    28 (24.3)   

  **CEA**                                                                                                                                                                                       

  ≤ 5.0 ng/ml                  238 (65.4)   104 (43.7)   134 (56.3)   0.670          135 (56.7)   103 (43.3)   0.340          155 (65.1)   83 (34.9)    0.451          187 (78.6)   51 (21.4)   0.603

  \> 5.0 ng/ml                 126 (34.6)   58 (46.0)    68 (54.0)                   78 (61.9)    48 (38.1)                   87 (69.0)    39 (31.0)                   96 (76.2)    30 (23.8)   

  **Cyfra21-1**                                                                                                                                                                                 

  ≤ 3.3 ng/ml                  195 (53.6)   84 (43.1)    111 (56.9)   0.556          109 (55.9)   86 (44.1)    0.276          128 (65.6)   67 (34.4)    0.715          152 (77.9)   43 (22.1)   0.921

  \> 3.3 ng/ml                 169 (46.4)   78 (46.2)    91 (53.8)                   104 (61.5)   65 (38.5)                   114 (67.5)   55 (32.5)                   131 (77.5)   38 (22.5)   

  **SCCA**                                                                                                                                                                                      

  ≤ 1.5 ng/ml                  283 (77.7)   131 (46.3)   152 (53.7)   0.200          177 (62.5)   106 (37.5)   **0.004**      198 (70.0)   85 (30.0)    **0.009**      231 (81.6)   52 (18.4)   **0.001**

  \> 1.5 ng/ml                 81 (22.3)    31 (38.3)    50 (61.7)                   36 (44.4)    45 (55.6)                   44 (54.3)    37 (45.7)                   52 (64.2)    29 (35.8)   
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

LN: lymph node. AD: adenocarcinoma. SCC: squamous cell carcinoma. SI: smoking index = (number of cigarettes per day) × (duration in years). \*P values \< 0.05 in bold.

###### 

Univariate and multivariate analyses of DFS and OS in all patients using the 50% cutoff value.

  Variables                DFS    OS                                                                                                                             
  ------------------------ ------ ---------------------- --------- --------------------- --------- ------ ---------------------- --------- --------------------- ----------
  All patients (n = 364)                                                                                                                                         
  Age (years)                                                                                                                                                    
  \< 60                    38.3   1.108 (0.857-1.433)    0.434                                     54.3   1.205 (0.899- 1.616)   0.212                           
  ≥ 60                     34.1                                                                    49.4                                                          
  Gender                                                                                                                                                         
  Male                     36.8   1.005 (0.771-1.309)    0.971                                     53.7   1.164 (0.856- 1.582)   0.333                           
  Female                   34.6                                                                    46.5                                                          
  Smoking Index (SI)                                                                                                                                             
  SI \< 400                37.9   1.394 (1.076- 1.807)   0.012     1.440 (1.105-1.876)   0.007     53.7   1.386 (1.028- 1.868)   0.032     1.442 (1.064-1.954)   0.018
  SI ≥ 400                 34.2                                                                    50.3                                                          
  Clinical stage                                                                                                                                                 
  I- II                    42.1   1.790 (1.373- 2.333)   \<0.001   1.758 (1.331-2.322)   \<0.001   59.5   1.899 (1.410- 2.558)   \<0.001   2.132 (1.559-2.914)   \< 0.001
  IIIA                     23.1                                                                    36.9                                                          
  Tumor size                                                                                                                                                     
  ≤ 3 cm                   37.3   0.944 (0.730- 1.221)   0.660     0.712 (0.542-0.935)   0.015     58.6   1.266 (0.941- 1.704)   0.119                           
  \> 3 cm                  36.0                                                                    46.2                                                          
  Regional LN metastasis                                                                                                                                         
  No                       42.6   1.586(1.226- 2.052)    \<0.001                                   61.3   1.729 (1.288-2.321)    \<0.001                         
  Yes                      28.1                                                                    46.3                                                          
  Histology                                                                                                                                                      
  AD                       32.5   0.890 (0.684- 1.157)   0.383                                     53.9   1.174 (0.875-1.575)    0.286                           
  SCC                      41.1                                                                    49.4                                                          
  Adjuvant treatment                                                                                                                                             
  No                       35.3   0.902 (0.693- 1.175)   0.445                                     47.1   0.631 (0.462-0.863)    0.004     0.483 (0.349-0.668)   \< 0.001
  Yes                      37.8                                                                    60.1                                                          
  EGFR mutation                                                                                                                                                  
  No                       47.3   0.930 (0.669- 1.291)   0.664                                     52.3   0.805 (0.551-1.178)    0.265                           
  Yes                      32.8                                                                    50.0                                                          
  NSE                                                                                                                                                            
  ≤ 15.2 ng/ml             36.5   0.997 (0.756- 1.314)   0.981                                     55.4   1.271 (0.939-1.720)    0.121                           
  \> 15.2 ng/ml            35.7                                                                    44.3                                                          
  CEA                                                                                                                                                            
  ≤ 5.0 ng/ml              43.3   1.747 (1.346- 2.268)   \<0.001   1.612 (1.234-2.107)   \<0.001   57.6   1.621 (1.205-2.181)    0.001     1.358 (1.003-1.840)   0.048
  \> 5.0 ng/ml             23.0                                                                    41.3                                                          
  Cyfra21-1                                                                                                                                                      
  ≤ 3.3 ng/ml              40.0   1.229 (0.950- 1.589)   0.117                                     57.9   1.473 (1.098-1.978)    0.010     1.501 (1.113-2.023)   0.008
  \> 3.3 ng/ml             32.0                                                                    45.6                                                          
  SCCA                                                                                                                                                           
  ≤ 1.5 ng/ml              37.8   1.352 (1.00- 1.828)    0.050     1.382 (1.015-1.881)   0.040     54.8   1.480 (1.057-2.073)    0.022                           
  \> 1.5 ng/ml             30.9                                                                    43.2                                                          
  PD-L1                                                                                                                                                          
  Negative                 38.9   1.546 (1.150- 2.079)   0.004     1.411 (1.044-1.908)   0.025     55.1   1.704 (1.220-2.380)    0.002     1.659 (1.179-2.333)   0.004
  Positive                 27.2                                                                    42.0                                                          
  PD-L2                                                                                                                                                          
  Negative                 39.5   1.276 (0.987- 1.651)   0.063                                     53.5   1.148 (0.856-1.539)    0.355                           
  Positive                 33.0                                                                    50.3                                                          

DFS: disease-free survival. OS: overall survival. HR: hazard ratio. CI: confidence interval. LN: lymph node. AD: adenocarcinoma. SCC: squamous cell carcinoma. SI: smoking index = (number of cigarettes per day) × (duration in years). \*P values \< 0.05 in bold.

###### 

Univariate analysis by PD-L1 expression (PD-L1+ versus PD-L1-, 50% Cutoff).

                                        DFS                   OS                                
  --------------- ------------- ------- --------------------- ----------- --------------------- -------------
  **variables**                 **N**   **HR(95% CI)**        **p\***     **HR(95% CI)**        **p\***
                  ALL           364     1.546(1.150-2.079)    **0.004**   1.704(1.220-2.380)    **0.002**
  **SI**          Stratified    364     1.394(1.076- 1.807)   **0.012**   1.386(1.028- 1.868)   **0.032**
                  SI\<400       203     1.259(0.801-1.979)    0.318       1.257(0.745-2.122)    0.391
                  SI≥400        161     1.704(1.137-2.554)    **0.010**   2.028(1.286-3.199)    **0.002**
  **SCCA**        Stratified    364     1.352(1.00- 1.828)    **0.050**   1.480(1.057-2.073)    **0.022**
                  ≤1.5 ng/ml    283     1.225(0.846- 1.773)   0.283       1.415(0.926- 2.162)   0.108
                  \>1.5 ng/ml   81      2.479(1.430- 4.296)   **0.001**   2.145(1.191- 3.864)   **0.011**
  **Histology**   Stratified    364     0.890(.684- 1.157)    0.383       1.174(0.875-1.575)    0.286
                  AD            206     1.141(0.758-1.718)    0.526       1.241(0.759-2.030)    0.390
                  SCC           158     2.149(1.382-3.340)    **0.001**   2.380(1.487-3.810)    **\<0.001**

AD: adenocarcinoma. SCC: squamous cell carcinoma. SI: smoking index = (number of cigarettes per day) × (duration in years). \* P values \<0.05 in bold.
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